Qiliqiangxin improves oxidized low-density lipoprotein-induced human coronary artery endothelial cells injury.

Changjiang Du¹#, Haiqin Lv²#, Guangyuan Meng³, Xiujuan Wang⁴, Haijun Cao⁵*

¹Department of Cardiovascular Surgery, the Central Hospital of Tai’an, 29 Long Tan Road, Tai’an, PR China
²Department of Pharmacy, the Affiliated Hospital of Taishan Medical University, Taishan Street, Tai’an, PR China
³The Central Hospital of Tai’an, 29 Long Tan Road, Tai’an, PR China
⁴The Information Engineering Institute of Taishan Medical University, 619 Chang Cheng Road, Tai’an, PR China
⁵Department of Anesthesia, the Central Hospital of Tai’an, 29 Long Tan Road, Tai’an, PR China

#These authors contributed equally to this work

Abstract

Qiliqiangxin (QL) has protective effect for the cardiovascular diseases treatment. This study aim to evaluate the effect of QL on the cell viability, cell apoptosis and caspase-3 activity in oxidized LDL (oxLDL)-induced Human Coronary Artery Endothelial Cells (HCAECs). HCAECs were treated with QL (0-1µg/ml) and oxLDL (150 μg/ml). The HCAECs viability was detected by cell proliferation assay and Lactate Dehydrogenase (LDH) release assay. The HCAECs apoptosis was evaluated by the annexin V-FITC assay. The activity of caspase-3 of HCAECs was measured by colorimetric caspase-3 assay. Cell migration assay and capillary-like tube formation assay on Matrigel were performed. Treatment of HCAECs to ox-LDL (150 μg/ml) decreased cell viability, stimulated apoptosis and enhanced caspase-3 activity. In addition, treatment with QL (0.5 µg/ml) alone did not affect cell viability and LDH release. Furthermore, the treatment with QL (0.5 µg/ml) significantly increased ox-LDL (150 µg/ml) decreased cell viability. Treatment with QL (0.5 µg/ml) reduced ox-LDL-stimulated apoptosis and caspase-3 activity in HCAECs in a dose-dependent manner. QL (0.5 µg/ml) abolished cell migration and tube formation. Our study demonstrated that QL prevents ox-LDL-induced HCAECs injury by decreasing the apoptosis via caspase-3 activity.

Keywords: Qiliqiangxin, Oxidized LDL, Apoptosis, Human microvascular endothelial cells, Caspase-3.

Accepted on November 22, 2017

Introduction

Dysfunction of vascular Endothelial Cells (ECs) has regarded as a high risk factor for the Atherosclerosis (AS) development [1,2]. It has also been demonstrated that ECs apoptosis induced atherosclerotic lesion development and plaque shedding [3-5]. Oxidized Low-Density Lipoprotein (ox-LDL), an important atherosclerotic risk factor, may induce ECs apoptosis during the pathogenesis of AS [6-8]. Hence, inhibition of ox-LDL induced ECs apoptosis may suggest new therapies in the AS treatment.

Qiliqiangxin (QLQX) is a traditional Chinese herbs medication, which are extracted from 11 distinct herbs including Radix Astragali, Ginseng, Salvia miltiorrhiza, Cortex Periplocae Sepii Radicis, Rhizoma Alismatis, Seasoned Orange Peel, Aconite Root, Carthamus tinctorius, Semen Lepidii Apetali, Polygonatum Odorati, and Rumulus Ginnamomi. Recent work has presented that QL is an effective agent in the cardiovascular diseases treatment [9,10]. QL showed the protective effects in the cardiovascular system via reducing myocardial apoptosis and cardiac fibrosis, thus protecting cardiac function. Moreover, QL Recently, another study reported that chronic administration of QL improved inflammation respond and improved energy metabolism progress. Although the protective regulation of QL on injured cells has achieved significant advance, the effect of QL on injury ECs is still largely elusive.

The excessive caspase-3 activity induced cell apoptosis in various types of cells [11-13]. Ox-LDL induced cells apoptosis via eliciting the caspase-3 activity [14-18]. However, the protective effect of QL to the ox-LDL induced ECs injury remains unknown. In the present study, we used Human Coronary Artery Endothelial Cells (HCAECs) to investigate the protective effects of QL on ox-LDL induced cell injury.
Methods

Materials
QL, provided by Shijiazhuang Yiling Pharmaceutical Co. Ltd (Shijiazhuang, Hebei, China), was diluted in culture media to various concentrations (0.25, 0.5, and 1.0 µg/ml). Recombinant human oxidized LDL was obtained from BioSun (Shanghai BioSun, Shanghai, China). Cell Counting Kit 8 (CCK-8, CK04) was obtained from Dojindo Laboratories (Kumamoto, Japan). Lactic acid dehydrogenase (LDH) assay kit was purchased from Bio Vision (CA, USA).

Cell culture and treatment
HCAECs were obtained from the American Type Culture Collection (ATCC) (Lot #61492256, Manassas, VA, USA). Cells were seeded in endothelial cell growth medium supplemented with 10% fetal bovine serum and 100 U/ml penicillin-streptomycin solution at 37°C, 5% CO₂ in an incubator. For the treatment, HCAECs were treated with QL (0-1 µg/ml) and ox-LDL (150 μg/ml) for 24 h.

Cell viability assay
The cell viability was performed by Cell Counting Kit-8 (CCK-8) kit (Dojindo, Kumamoto, Japan) according to the manufacturer's protocol [19]. HCAECs (5 × 10⁴/well) were incubated in 96-well plates with QL (0-1 µg/ml) and ox-LDL (150 µg/ml) for 24 h, then CCK-8(10 µL) reagent was added for 2 h at 37°C. The plates were detected at 450 nm by a microplate reader (Bio-Rad technology, CA, USA).

LDH release assay
HCAECs (5 × 10⁴/well) were cultured in 96-well plates with QL (0-1 µg/ml) and ox-LDL (150 µg/ml) for 24 h. The LDH released into the cell media were used to detect LDH activity using an analysis kit according to the manufacturer’s instructions.

Flow cytometry
The percentage of apoptotic cells was calculated by annexin V-FITC and Propidium Iodide (PI) kit according to the manufacturer’s protocol. In brief, HCAECs (2 × 10⁵/well) were cultured in 6-well plates with QL (0-1 µg/ml) and ox-LDL (150 µg/ml) for 24 h. Then cells were harvested and incubated annexin V-FITC and PI with for 15 min at room temperature in the dark. The cell apoptotic rates were then quantified by flow cytometry.

Measurement of caspase-3 activity
The activity of caspase-3 was detected by a colorimetric caspase-3 assay kit (Sigma, St. Louis, MO, USA) according to the manufacturer’s protocol [20]. HCAECs (2 × 10⁵/well) were cultured in 6-well plates with QL (0-1 µg/ml) and ox-LDL (150 µg/ml) for 24 h. The cell lysate were added with caspase-3 substrate at 37°C for 90 min. The plates were detected at 405 nm by a microplate reader (Bio-Rad technology, CA, USA).

Cell migration assay
Cell migration assay were presented in 24-well Transwell plates with 8 µm pores (Corning, Santa Clara, CA, USA). HCAECs (5 × 10⁵) were cultured in the upper culture chambers, while basic medium with 10% FBS was added to the lower chambers for 6 h. The migrated cells were counted and assessed. Filters were stained with Calcein AM (2 µg/ml) for 15 min. Three random fields were counted by a Nikon Eclipse TS100 microscope (Nikon, Tokyo, Japan).

Tube forming assay
The tube formation was assessed by precoated Matrigel 24-well culture plates, as previously described [19]. Matrigel (BD Bioscience, San Jose, CA, USA) was added to each well of the 96-well culture plates at 37°C for 1 h for polymerization. The cells were added to the Matrigel-coated wells and incubated at 37°C in 5% CO₂ atmosphere. The tube formation was photographed by a Nikon Eclipse TS100 microscope (Nikon, Tokyo, Japan).

Statistical analysis
Differences between treatments were assessed by one-way ANOVA followed by a Tukey test (Bartlett test p>0.05) to compare mean of treatments with controls. Results are given as mean ± standard error of mean.

Results
QL increases cell viability in ox-LDL-exposed HCAECs
Firstly, we detected the cytotoxicity of QL on HCAECs. Our data showed that QL (1 µg/ml) treatment did not affect HCAECs cell viability for 24 h (p>0.05 vs. control) (Figure 1a). Additionally, ox-LDL (150 μg/ml) treatment decreased cell viability for 24 h (Figure 1b). Further, our data showed that QL suppresses ox-LDL induced the LDH release in a dose dependent manner (Figure 1c).

QL inhibits LDH release in ox-LDL-exposed HCAECs
The LDH release were used to assess whether QL affect ox-LDL-induced HCAECs injuries. As shown in Figure 2a, QL (1 µg/ml) did not affect the LDH release in HCAECs. Moreover, ox-LDL (150 µg/ml) treatment elevated LDH release in HCAECs, compared with control group (P<0.05) (Figure 2b). Treatment with QL (1 µg/ml) reduced ox-LDL induced the LDH release in a dose dependent manner (Figure 2c).

QL inhibits ox-LDL-induced apoptosis in HCAECs
To analyse the anti-apoptotic effects of QL on ox-LDL-treated HCAECs, annexin V-PI and flow cytometry assay were
performed. QL (1 µg/ml) did not affect the apoptosis in HCAECs (Figure 3a).

As seen in Figure 3b, ox-LDL increased HCAECs apoptosis compared with control (P<0.01). Treatment with QL (1 µg/ml) reduced ox-LDL increased HCAECs apoptosis in a dose dependent manner (Figure 3c).

**Figure 1.** QL increases cell viability in ox-LDL-exposed HCAECs. Cell viability was evaluated by CCK-8 assay. (A) HCAECs were incubated with QL (1 µg/ml) for 24 h. (B) HUVECs were incubated with ox-LDL (150 µg/ml) for 24 h. (C) HCAECs were incubated with QL (1 µg/ml) and ox-LDL (150 µg/ml) for 24 h. Data are presented as means ± SEM of 3 independent experiments. *p<0.05 vs. control group.

**Figure 2.** QL inhibits LDH release in ox-LDL-exposed HCAECs. (A) HCAECs were incubated with QL (1 µg/ml) for 24 h. (B) HUVECs were incubated with ox-LDL (150 µg/ml) for 24 h. (C) HCAECs were incubated with QL (1 µg/ml) and ox-LDL (150 µg/ml) for 24 h. Data are presented as means ± SEM of 3 independent experiments. *p<0.05 vs. control group.

**QL inhibits ox-LDL-induced caspase-3 activity in HCAECs**

Subsequently, we detected the effect of QL on ox-LDL-induced caspase-3 activity in HCAECs. QL (1 µg/ml) did not affect the caspase-3 activity in HCAECs (Figure 4a). The ox-LDL treatment enhanced the caspase-3 activity (P<0.01) (Figure 4b). Moreover, treatment of HCAECs with QL (1 µg/ml) inhibited ox-LDL stimulates caspase-3 activation (Figure 4c), implied that HCAECs may undergo caspase independent apoptosis signal pathway when treated with QL (1 µg/ml) and ox-LDL.

**Figure 3.** QL inhibits cell apoptosis in ox-LDL-exposed HCAECs. (A) HCAECs were incubated with QL (1 µg/ml) for 24 h. (B) HUVECs were incubated with ox-LDL (150 µg/ml) for 24 h. (C) HCAECs were incubated with QL (1 µg/ml) and ox-LDL (150 µg/ml) for 24 h. Data are presented as means ± SEM of 3 independent experiments. *p<0.05 vs. control group.

**Figure 4.** QL inhibits caspase-3 activity in ox-LDL-exposed HCAECs. (A) HCAECs were incubated with QL (1 µg/ml) for 24 h. (B) HUVECs were incubated with ox-LDL (150 µg/ml) for 24 h. (C) HCAECs were incubated with QL (1 µg/ml) and ox-LDL (150 µg/ml) for 24 h. Data are presented as means ± SEM of 3 independent experiments. *p<0.05 vs. control group.

**QL promoted migration in ox-LDL treated HCAECs**

To detect the protective effects of QL on ox-LDL-treated HCAECs, Transwell migration assay were performed. As seen in Figure 5, ox-LDL increased HCAECs apoptosis compared with control (P<0.01). Treatment with QL (1 µg/ml) reversed ox-LDL reduced HCAECs migration.

**Figure 5.** QL promotes migration in ox-LDL treated HCAECs. (A) HCAECs were incubated with QL (1 µg/ml) for 24 h. (B) HUVECs were incubated with ox-LDL (150 µg/ml) for 24 h. (C) HCAECs were incubated with QL (1 µg/ml) and ox-LDL (150 µg/ml) for 24 h. Data are presented as means ± SEM of 3 independent experiments. *p<0.05 vs. control group.

**QL promoted tube formation in ox-LDL treated HCAECs**

To detect the protective effects of QL on ox-LDL-treated HCAECs, tube formation assay were performed. As seen in Figure 6, ox-LDL reduced HCAECs tube formation compared with control (P<0.01). Treatment with QL (1 µg/ml) reversed ox-LDL reduced HCAECs tube formation.
Discussion

The endothelial cells dysfunction is a key event in the atherosclerosis progress development. It is also well-known that ECs apoptosis induces atherosclerotic plaques and thrombosis formation, which could cause coronary artery disease [21]. Exposure to ox-LDL induced endothelial cells apoptosis. Considering the key role of ox-LDL in the atherosclerosis progression development, we used ox-LDL-treated HCAECs as the in vitro model to evaluate the effect of QL. Firstly, our study demonstrated that QL increased ox-LDL-treated HCAECs viability in a dose dependent manner. Then, our data showed that QL decreased ox-LDL-treated HCAECs apoptosis in a dose dependent manner. Moreover, caspase-3 activity has a key role in cell apoptosis. Our results showed that QL decreased ox-LDL-induced caspase-3 activity, which are in accordance with the data that QL protected HCAECs from ox-LDL induced cell apoptosis. Thus, our results suggested that QL protects ox-LDL-enhanced HCAECs apoptosis by reducing caspase-3 activity.

It is well known that angiogenesis plays a critical role in the recovery of cardiac function in response to a number of injuries [22]. ECs are important for myocardial angiogenesis and directly affect with myocardium. The previous study suggested that QL reduced cardiac myocytes apoptosis. Our data implied QL maintained physiological function of ECs, characterized by enhanced migration and tube formation ability.

All the results implied that the apoptotic signaling might be essential for the protective effects of QL on ox-LDL-treated HCAECs. So QL may be used as a new therapeutic agent for atherosclerosis. Furthermore, molecular mechanisms should be investigated in vitro and in vivo models.

Conflict of Interest

The authors did not report any conflict of interest.

References


*Correspondence to
Haijun Cao
Department of Anesthesia
The Central Hospital of Tai’an
PR China